Other · developed by Protagonist Therapeutics
PN-943 is an orally administered agent studied in chronic moderate to severe ulcerative colitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04504383 | Phase 2 | Ulcerative Colitis Chronic Moderate | Completed | PTGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ulcerative Colitis Chronic ModerateUlcerative Colitis Chronic Severe
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTGX page.
See PTGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTGX catalysts and pipeline →